RESUMO
Overwhelming post-splenectomy infection (OPSI) is a serious complication of asplenia and is associated with encapsulated organisms, most commonly Streptococcus pneumoniae, but also Haemophilus influenzae and Neisseria meningitidis. We aimed to estimate the risk of infection in this patient group. We reviewed data collected by the Victorian Spleen Registry in Australia. On registration, all patients are asked about significant infections requiring admission to hospital for intravenous antibiotics; those requiring admission to ICU were defined as OPSI. In the 3274 asplenic patients registered 492 patients reported at least one episode of infection. There were 47 episodes of OPSI requiring intensive care (incidence rate 1·11/1000 patient-years). The risk of OPSI was highest in older patients, and there were no statistically significant differences in incidence by reason for splenectomy except for a higher rate in patients with medical hyposplenia. This study reinforces that post-splenectomy infection is a clinically significant but uncommon complication, and that fulminant infection requiring intensive care is a minority of all infections.
Assuntos
Bacteriemia/epidemiologia , Bacteriemia/patologia , Complicações Pós-Operatórias/epidemiologia , Complicações Pós-Operatórias/patologia , Esplenectomia/efeitos adversos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Medição de Risco , Vitória/epidemiologia , Adulto JovemRESUMO
The role of panfungal polymerase chain reaction (PCR) assays for diagnosis of invasive fungal disease (IFD) is inadequately defined. We describe the use of an internal transcribed spacer 1 (ITS-1) region-directed panfungal PCR in this context at a tertiary referral transplant center. A retrospective review of patients at Alfred Health, Melbourne, Australia (2009-2014) who had clinical samples referred for panfungal PCR testing was conducted. Baseline patient characteristics, antifungal drug history, fungal culture/histopathology, and radiology results were recorded. For bronchoalveolar lavage (BAL) fluid samples, identification of a fungus other than a Candida spp. was defined as a potential pathogen.Of 138 panfungal PCR tests (108 patients), 41 (30%) were positive for a fungal product. Ninety-seven percent (134/138) of specimens were from immunocompromised hosts. Thirteen percent (19/138) of panfungal PCR positive results were for potential pathogens and potential pathogens were detected more frequently in tissue as compared with BAL (12/13 vs. 6/26; P = .0001). No positive panfungal PCR results were obtained from CSF specimens. If histopathology examination was negative, panfungal PCR identified a potential pathogen in only 12% (11/94) of specimens. For the 20 culture negative/histopathology positive specimens, diagnosis of IFD to causative species level by panfungal PCR occurred in 35% (6/20).Sterile site specimens, in particular tissue, were more frequently panfungal PCR positive for potential pathogens than BAL. The utility of panfungal PCR appears greatest in tissue specimens, as an adjunct to histopathology to improve diagnostic sensitivity and specificity. Based on the results of this study we are now only testing tissue specimens by panfungal PCR.
Assuntos
Técnicas de Diagnóstico Molecular/métodos , Micoses/diagnóstico , Reação em Cadeia da Polimerase/métodos , Austrália , DNA Fúngico/genética , DNA Espaçador Ribossômico/genética , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Sensibilidade e EspecificidadeRESUMO
Mucormycosis is associated with significant morbidity and mortality. We reviewed patients with mucormycete isolated at Alfred Health, Australia. A retrospective review of 66 patients with mucormycete(s) identified, between 1 April 2008 and 30 June 2014. Baseline demographic, microbiological, radiological, treatment/outcome data were recorded. Site of isolation was sinopulmonary in 77% and skin/soft tissue in 21%. A total of 32% of cases were proven-IFD, 12% probable-IFD and 56% were defined as no-IFD (or colonisation). Rhizopus spp. was identified in 48%. Comparing probable/proven-IFD with no-IFD/colonisation, more patients were postallogeneic stem cell transplantation (28% vs. 0%, P < 0.01) and were receiving immunosuppressive therapy (59% vs. 24%, P < 0.01) including prednisolone >20 mg daily (24% vs. 5%, P = 0.04). A total of 93% of patients with proven/probable IFD received treatment while 30% of no-IFD/colonisation were treated. A total of 72% of patients with proven/probable IFD and 92% of those with colonisation had no further mucormycete isolated. Thirty day mortality was higher in the proven/probable-IFD cohort (24%) compared with no-IFD/colonisation (3%) (P = 0.02). Mucormycosis remains uncommon, with 56% of cases not associated with clinical infection. Immunosuppressive therapy remains strongly associated with mucormycosis. Mortality remains high in those with proven/probable IFD.
Assuntos
Mucorales/classificação , Mucormicose/epidemiologia , Estudos de Coortes , Feminino , Humanos , Pulmão/microbiologia , Masculino , Pessoa de Meia-Idade , Mucorales/isolamento & purificação , Mucormicose/mortalidade , Mucormicose/terapia , Seios Paranasais/microbiologia , Estudos Retrospectivos , Fatores de Risco , Pele/microbiologia , Infecções dos Tecidos Moles/epidemiologia , Infecções dos Tecidos Moles/mortalidade , Centros de Atenção Terciária , Resultado do Tratamento , Vitória/epidemiologiaRESUMO
A total of 421 methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates were tested for ceftaroline susceptibility by Etest (bioMérieux). A multidrug resistant phenotype was found in 40.9%, and clonal complex 239 (CC239) was found in 33.5%. Ceftaroline nonsusceptibility (MIC, >1.0 µg/ml) was 16.9% overall. Nonsusceptibility was significantly higher in CC239 (41.1%, 58/141) and in isolates with a multidrug resistant phenotype (35.5%, 61/172) compared with comparators (P < 0.0001). Nonsusceptibility of common multidrug resistant MRSA clones limits the empirical use of ceftaroline for these infections.
Assuntos
Antibacterianos/farmacologia , Cefalosporinas/farmacologia , Farmacorresistência Bacteriana Múltipla , Staphylococcus aureus Resistente à Meticilina/efeitos dos fármacos , Austrália , Células Clonais , Humanos , Meticilina/farmacologia , Staphylococcus aureus Resistente à Meticilina/crescimento & desenvolvimento , Staphylococcus aureus Resistente à Meticilina/isolamento & purificação , Testes de Sensibilidade Microbiana , Fenótipo , Infecções Estafilocócicas/tratamento farmacológico , Infecções Estafilocócicas/microbiologia , CeftarolinaRESUMO
The impact of vanB vancomycin-resistant enterococci (VRE) bacteraemia on length of stay (LOS) in hospital, after adjusting for the time-varying nature of enterococcal bacteraemia (variable onset of bacteraemia post-admission), is unknown. Survival analyses (time-varying Cox and competing risks regression) were performed on vanB VRE bacteraemia patients, matched 1:1 with vancomycin-susceptible enterococci bacteraemia patients to determine the factors associated with LOS in these patients. In Cox regression analysis, vanB VRE bacteraemia, intensive-care-unit admission, Charlson co-morbidity index score ⩾4, and an increase in the time to receive appropriate antibiotics were associated with prolonged LOS. Competing risks regression which accounts for the influence of in-patient mortality on the ability to observe the event discharge alive from hospital suggests that, vanB VRE bacteraemia was not significantly associated with prolonged LOS. For the first time, the rate of discharge from hospital in patients with vanB VRE bacteraemia has been quantified.
Assuntos
Antibacterianos/uso terapêutico , Bacteriemia/tratamento farmacológico , Bacteriemia/microbiologia , Infecção Hospitalar/tratamento farmacológico , Infecção Hospitalar/microbiologia , Tempo de Internação/estatística & dados numéricos , Resistência a Vancomicina , Enterococos Resistentes à Vancomicina/isolamento & purificação , Bacteriemia/mortalidade , Infecção Hospitalar/mortalidade , Feminino , Humanos , Masculino , Análise de Sobrevida , Enterococos Resistentes à Vancomicina/efeitos dos fármacosRESUMO
BACKGROUND: Healthcare-associated Staphylococcus aureus bloodstream infection (HA-SAB) causes preventable harm in hospitalized patients. Currently, there is no standardized method available to review HA-SAB events in order to identify and target preventable risks requiring action at an organizational level. AIM: To develop a tool to classify SAB events, and the necessary response actions, according to the degree of preventability. METHODS: Following a literature review, a tool was developed. Consensus feedback and development of the tool was sought from experts (N = 11) in healthcare-associated infection surveillance using a Delphi technique. The completed tool was retrospectively applied to HA-SAB events (N = 43) that occurred at a large healthcare organization. FINDINGS: Survey completion rates were high (91-100%). Clinicians' poor adherence to infection prevention practices and lack of engagement with feedback processes was established as the key modifiable element. A second key theme was the need for structured and detailed response actions. This feedback was incorporated into the tool and refined until consensus on all elements was achieved. Pilot application of the tool found that 56% of HA-SAB events were highly or possibly preventable; modifiable factors for HA-SAB prevention were not present in the remainder of cases. CONCLUSION: A prevention assessment and response tool was successfully developed via a consensus method to assist organizations in investigating and responding to individual cases of HA-SAB and identify future priority areas for SAB reduction strategies. Wider use of the tool with routine surveillance activities is required to evaluate impact upon infection prevention programmes and patient outcomes.
Assuntos
Bacteriemia , Infecção Hospitalar , Infecções Estafilocócicas , Bacteriemia/epidemiologia , Bacteriemia/prevenção & controle , Infecção Hospitalar/epidemiologia , Infecção Hospitalar/prevenção & controle , Atenção à Saúde , Humanos , Estudos Retrospectivos , Infecções Estafilocócicas/epidemiologia , Infecções Estafilocócicas/prevenção & controle , Staphylococcus aureusRESUMO
INTRODUCTION: The confirmation or analysis and exclusion of a diagnosis of neurosyphilis has long presented a challenge for infectious diseases clinicians. The authors reviewed the concordance between cerebrospinal fluid (CSF) analysis and the subsequent antibiotic strategy for patients undergoing evaluation of a diagnosis of neurosyphilis. METHODS: All patients with positive serum syphilis serology referred for CSF analysis between January 2009 and May 2016 were included. Indications for CSF analysis were determined by review of the hospital electronic medical records. CSF parameters were determined from the hospital pathology database. Cases were defined as either 'confirmed', 'supportive' of, or 'not supportive' of a diagnosis of neurosyphilis based on existing definitions. Subsequent therapy was defined as for neurosyphilis, late latent primary syphilis or no therapy based on existing guidelines. RESULTS: Of 131 patients reviewed, 95.4% were male and HIV co-infected (74%). A confirmed diagnosis of neurosyphilis was met by fourteen patients (10.7%). All but two of these were treated with a neurosyphilis-directed regimen. Of the 58 patients treated with neurosyphilis antibiotics, 17.2% had no CSF findings suggestive of the diagnosis. Seventy-three patients were not treated for neurosyphilis; however 35 of these met the CSF criteria for a diagnosis supportive of neurosyphilis. CONCLUSIONS: The results of routine CSF analysis in patients with a possible diagnosis of neurosyphilis are inconsistently applied in the clinical setting, calling into question the value of routine CSF. Empirical neurosyphilis treatment should be considered up front in patients with high pre-test probability of the diagnosis.
Assuntos
Antibacterianos/uso terapêutico , Infecções por HIV/complicações , Neurossífilis/diagnóstico , Treponema pallidum/imunologia , Adulto , Idoso , Estudos de Coortes , Coinfecção , Feminino , Teste de Absorção do Anticorpo Treponêmico Fluorescente , Hospitais , Humanos , Masculino , Pessoa de Meia-Idade , Neurossífilis/líquido cefalorraquidiano , Neurossífilis/complicações , Neurossífilis/dietoterapia , Punção Espinal , Sorodiagnóstico da SífilisRESUMO
Asplenic or hyposplenic patients are at risk of fulminant sepsis. This entity has a mortality of up to 50%. The spectrum of causative organisms is evolving as are recommended preventive strategies, which include education, prophylactic and standby antibiotics, preventive immunizations, optimal antimalarial advice when visiting endemic countries and early management of animal bites. However, there is evidence that adherence to these strategies is poor. Consensus-updated guidelines have been developed to help Australian and New Zealand clinicians and patients in the prevention of sepsis in asplenic and hyposplenic patients.
Assuntos
Guias de Prática Clínica como Assunto/normas , Sepse/prevenção & controle , Esplenopatias/terapia , Animais , Humanos , Sepse/epidemiologia , Sepse/etiologia , Esplenectomia/métodos , Esplenopatias/complicações , Esplenopatias/epidemiologiaRESUMO
Few studies have used molecular epidemiological methods to study transmission links to clinical isolates in intensive care units. Ninety-four multidrug-resistant organisms (MDROs) cultured from routine specimens from intensive care unit (ICU) patients over 13 weeks were stored (11 meticillin-resistant Staphylococcus aureus (MRSA), two vancomycin-resistant enterococci and 81 Gram-negative bacteria). Medical staff personal mobile phones, departmental phones, and ICU keyboards were swabbed and cultured for MDROs; MRSA was isolated from two phones. Environmental and patient isolates of the same genus were selected for whole genome sequencing. On whole genome sequencing, the mobile phone isolates had a pairwise single nucleotide polymorphism (SNP) distance of 183. However, >15,000 core genome SNPs separated the mobile phone and clinical isolates. In a low-endemic setting, mobile phones and keyboards appear unlikely to contribute to hospital-acquired MDROs.
Assuntos
Telefone Celular , Computadores , Infecção Hospitalar/microbiologia , Microbiologia Ambiental , Bactérias Gram-Negativas/isolamento & purificação , Staphylococcus aureus Resistente à Meticilina/isolamento & purificação , Enterococos Resistentes à Vancomicina/isolamento & purificação , Infecção Hospitalar/epidemiologia , Transmissão de Doença Infecciosa , Genótipo , Bactérias Gram-Negativas/classificação , Bactérias Gram-Negativas/genética , Humanos , Unidades de Terapia Intensiva , Staphylococcus aureus Resistente à Meticilina/classificação , Staphylococcus aureus Resistente à Meticilina/genética , Epidemiologia Molecular , Polimorfismo de Nucleotídeo Único , Centros de Atenção Terciária , Enterococos Resistentes à Vancomicina/classificação , Enterococos Resistentes à Vancomicina/genética , Sequenciamento Completo do GenomaRESUMO
Acinetobacter has recently risen in prominence as a nosocomial pathogen, particularly due to increasing antibiotic resistance. The aim of this study was to describe changes in rates and antibiotic susceptibility patterns of Acinetobacter in three Melbourne hospitals. This was a retrospective review of microbiology records over five years. The rates of new clinical isolates of Acinetobacter per 10 000 discharges per quarter were calculated. Other information collected included antibiotic susceptibility patterns, age, gender, length of stay and ward [intensive care unit (ICU) or non-ICU]. Rates increased substantially at two hospitals, but not at the third. Increasing numbers at one hospital were associated with antibiotic resistance. Most first isolates were identified while the patient was in the ICU. Many isolates were from respiratory specimens, although a significant proportion was from blood. This study documents the establishment of Acinetobacter as a nosocomial pathogen in two Melbourne hospitals and serves as a warning for the future.
Assuntos
Infecções por Acinetobacter/epidemiologia , Infecções por Acinetobacter/microbiologia , Acinetobacter/isolamento & purificação , Infecção Hospitalar/epidemiologia , Infecção Hospitalar/microbiologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Austrália/epidemiologia , Bacteriemia/microbiologia , Cuidados Críticos , Farmacorresistência Bacteriana , Feminino , Hospitais , Humanos , Incidência , Estudos Longitudinais , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Doenças Respiratórias/microbiologia , Estudos RetrospectivosRESUMO
OBJECTIVES: To identify and collect clinical isolates of multi-drug resistant Gram negative bacteria and to perform antimicrobial susceptibility testing using an extended panel of antibiotics including tigecycline, colistin, aztreonam, piperacillin/tazobactam and ampicillin/sulbactam. METHODS: Minimum inhibitory concentrations (MICs) using the Epsilometer test (E-test) methodology were determined for 28 distinct multi-drug resistant Gram negative isolates from patients in the intensive care unit (ICU). RESULTS: Tigecycline had good in vitro activity against Acinetobacter species and Enterobacter cloacae, and colistin had potent in vitro activity against Acinetobacter, E. cloacae and Pseudomonas aeruginosa. Enterobacter cloacae and Serratia marcescens but not P. aeruginosa or Acinetobacter species were susceptible to piperacillin/tazobactam. Ampicillin/sulbactam had poor in vitro activity for most isolates tested. The activity of tigecycline and colistin did not appear to be affected by the presence of extended spectrum beta-lactamases (ESBLs) and metallo-beta-lactamases (MBLs) and aztreonam maintained its in vitro activity against the Enterobacteriaceae tested despite the presence of MBLs. CONCLUSIONS: Tigecycline and colistin have potent in vitro activity and might have useful therapeutic activity in patients with infections due to multi-drug resistant Acinetobacter species and E. cloacae, including those harbouring ESBLs and MBLs. In addition, colistin demonstrated potent in vitro activity against multi-drug resistant P. aeruginosa.
Assuntos
Antibacterianos/farmacologia , Colistina/farmacologia , Resistência a Múltiplos Medicamentos/efeitos dos fármacos , Bactérias Gram-Negativas/efeitos dos fármacos , Testes de Sensibilidade Microbiana , Minociclina/análogos & derivados , Humanos , Unidades de Terapia Intensiva , Minociclina/farmacologia , TigeciclinaRESUMO
BACKGROUND: Strongyloides stercoralis is a nematode human parasite with a global prevalence that is able to maintain a prolonged infestation by means of its autoinfective life cycle. Immunosuppression may result in a life-threatening hyperinfection syndrome. Recent changes in migration have resulted in the arrival of many immigrants from endemic areas. As to whether physicians are alert to the risks of strongyloidiasis in these patient groups is unclear. The aim of the study was to assess the risks posed by chronic strongyloidiasis in patients presenting to a tertiary referral centre and the need for screening of immigrant patients before immunosuppression. METHODS: The study comprised a retrospective review of cases of strongyloidiasis presenting to the Alfred Hospital, Melbourne. Thirty-three cases were diagnosed by either positive serology or faecal microscopy between January 1998 and January 2005. The medical records for 29 cases were examined with regard to demographics, clinical features and complications. RESULTS: Two major groups were identified: immigrants (17) and returned travellers (11). Six immigrants, but no returned traveller, developed a hyperinfective syndrome. Five immigrants received immunosuppressive therapies before developing symptoms of hyperinfection and this was complicated by life-threatening sepsis in two patients. Diagnosis was frequently delayed in the immigrant group who were significantly more likely to present with respiratory symptoms. Four immigrants and two returned travellers were treated with corticosteroids for symptoms that were probably related to larval migration. CONCLUSION: Before giving immunosuppressive therapies, patients with a history of potential exposure must be investigated for strongyloidiasis and consideration given to empirical treatment.
Assuntos
Emigração e Imigração , Hospitais Urbanos , Strongyloides stercoralis , Estrongiloidíase/diagnóstico , Estrongiloidíase/epidemiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Animais , Austrália/epidemiologia , Feminino , Humanos , Imunossupressores/farmacologia , Imunossupressores/uso terapêutico , Masculino , Pessoa de Meia-Idade , Encaminhamento e Consulta , Estudos Retrospectivos , Fatores de Risco , Strongyloides stercoralis/efeitos dos fármacos , Estrongiloidíase/tratamento farmacológico , ViagemRESUMO
BACKGROUND: Two meticillin-resistant Staphylococcus aureus (MRSA) clones, sequence type (ST) 22 and ST239, have successfully spread globally. Across Australia, ST22 has supplanted ST239 as the main healthcare-associated MRSA. To understand the reasons underlying this shift, the epidemiology and clinical features of infections due to ST22 and ST239 MRSA isolates from a tertiary hospital in Melbourne, Australia were compared. METHODS: Over six months, consecutive MRSA isolates with clinical data were collected from specimens referred to Alfred Health Pathology (AHP). Isolates were genotyped by a multi-locus-sequence-typing-based high-resolution melting method. FINDINGS: Three hundred and twenty-eight of 1079 (30%) S. aureus isolated by AHP were MRSA. Of these, 313 were genotyped; 78 (25%) were clonal complex (CC) 22 (representing ST22) and 142 (45%) were CC239 (representing ST239). Common clinical syndromes included skin or soft tissue, respiratory tract and osteo-articular infections. On multi-variate logistic regression, compared with CC239, CC22 was associated with older patients [adjusted odds ratio (aOR) 1.04 for each year increase, 95% confidence interval (CI) 1.02-1.07)], and patients from subacute hospitals (aOR 2.7, 95% CI 1.2-5.8) or long-term care facilities (LTCFs; aOR 5.5, 95% CI 2.0-14.5). Median time from patient admission to MRSA isolation was nine days for CC239 and one day for CC22 (P < 0.01). MRSA strain epidemiology varied according to hospital unit. CONCLUSIONS: CC22 and CC239 MRSA have differing ecological niches. CC22 is associated with elderly patients in LTCFs, and CC239 is associated with nosocomial acquisition. Infection control strategies involving LTCFs and their residents will likely be required to achieve continued MRSA control.
Assuntos
Infecção Hospitalar/epidemiologia , Infecção Hospitalar/microbiologia , Genótipo , Staphylococcus aureus Resistente à Meticilina/classificação , Staphylococcus aureus Resistente à Meticilina/isolamento & purificação , Infecções Estafilocócicas/epidemiologia , Infecções Estafilocócicas/microbiologia , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Austrália/epidemiologia , Infecção Hospitalar/patologia , Ecossistema , Feminino , Humanos , Controle de Infecções , Masculino , Staphylococcus aureus Resistente à Meticilina/genética , Pessoa de Meia-Idade , Tipagem de Sequências Multilocus , Infecções Estafilocócicas/patologia , Staphylococcus aureus , Centros de Atenção TerciáriaRESUMO
International travellers with immunocompromising conditions such as human immunodeficiency virus (HIV) infection, solid organ transplantation (SOT) and haematopoietic stem cell transplantation (HSCT) are at a significant risk of travel-related illnesses from both communicable and non-communicable diseases, depending on the intensity of underlying immune dysfunction, travel destinations and activities. In addition, the choice of travel vaccinations, timing and protective antibody responses are also highly dependent on the underlying conditions and thus pose significant challenges to the health-care providers who are involved in pre-travel risk assessment. This review article provides a framework of understanding and approach to aforementioned groups of immunocompromised travellers regarding pre-travel risk assessment and management; in particular travel vaccinations, infectious and non-infectious disease risks and provision of condition-specific advice; to reduce travel-related mortality and morbidity.
Assuntos
Controle de Doenças Transmissíveis , Hospedeiro Imunocomprometido , Transplantados , Viagem , Vacinação , Infecções por HIV/imunologia , Transplante de Células-Tronco Hematopoéticas , Células-Tronco Hematopoéticas , Humanos , Transplante de Órgãos , Profilaxia Pré-Exposição , Medição de RiscoRESUMO
OBJECTIVE: To describe patterns of health-service usage and the resulting costs in 1992-1993 for Australian men. DESIGN: A prospective survey, stratified by phase of illness. SETTING: Hospital and community-based care. PATIENTS: A total of 128 homosexual men: 20 in phase 1 (CD4+ count > or = 500 x 10(6)/l), 31 in phase 2 (CD4+ count < 500 and > or = 200 x 10(6)/l), 30 in phase 3 (CD4+ count < 200 x 10(6)/l), and 47 in phase 4 (AIDS). MAIN OUTCOME MEASURES: Mean monthly service usage rates and costs. RESULTS: Health-service utilization increased and became more hospital-based as illness worsened; the main exception was use of antiretroviral drugs, which peaked in phases 2 and 3. Hospital admission was rare before diagnosis of AIDS. Hospital bed-days per patient per month averaged 3.3 for AIDS patients until the final 3 months of life increasing to 15.8 in the 3 months before death. Mean monthly costs (in 1992-1993 Australian dollars) were $331 [95% confidence interval (CI), 218-455] in phase 1, $667 (95% CI, 540-836) in phase 2, $1372 (95% CI, 1044-1776) in phase 3, and $4615 (95% CI, 3456-5985) for AIDS patients until the last 3 months of life and $13,308 (95% CI, 10,538-16,516) in the 3 months before death. Drugs comprised 57% of total costs in phase 1, but only 30% of costs for patients with AIDS, whereas hospital bed-days comprised 10% of phase 1 costs and 60% of AIDS costs. CONCLUSIONS: Health-care utilization and resulting costs increased with severity of illness, and were particularly high for AIDS patients in the 3 months before death. Service-utilization patterns and components of costs varied between each phase.
Assuntos
Síndrome da Imunodeficiência Adquirida/economia , Serviços de Saúde Comunitária/estatística & dados numéricos , Custos de Cuidados de Saúde , Síndrome da Imunodeficiência Adquirida/epidemiologia , Austrália/epidemiologia , Serviços de Saúde Comunitária/economia , Homossexualidade Masculina , Humanos , MasculinoRESUMO
BACKGROUND: Human cytomegalovirus (HCMV) reactivation and disease remain relatively common in lung transplant recipients (LTR) despite the use of ganciclovir prophylaxis protocols for all HCMV at-risk patients. The specific aims of this study were to (1) describe the HCMV DNA viral load in the peripheral blood leukocytes (PBL) of a cohort of LTR during the first 6 months after lung transplantation; (2) prospectively determine whether HCMV DNA viral load predicts episodes of HCMV pneumonitis in LTR; and (3) study the effect of ganciclovir on HCMV viral load. METHODS: Competitive polymerase chain reaction using an internal standard and fluorometric detection were used to quantitate HCMV DNA in the PBL of a cohort of 26 LTR monthly for the first 6 months after transplantation (145 samples). All patients were treated with standard triple immunosuppression, and ganciclovir prophylaxis was given to all at-risk LTR (donor or recipient HCMV seropositive) for at least 8 weeks after transplantation. RESULTS: Thirteen episodes of histopathologically proven HCMV pneumonitis in nine subjects occurred during follow-up with a wide intra- and intersubject variation in the HCMV DNA PBL levels. HCMV detection had a sensitivity of 92% and specificity of 76% for HCMV pneumonitis (negative likelihood ratio, 9.5), whereas greater than 10-fold increases in HCMV DNA load had a specificity of 93% and sensitivity of 67% (positive likelihood ratio, 11). HCMV DNA detection had an adjusted odds ratio for HCMV pneumonitis of 107 (95% confidence interval, 14-821; P<0.005). In those with detectable HCMV DNA in PBL (n=44), HCMV DNA levels were 4.4 (95% confidence interval, 1.2-16.8) times higher in those with HCMV pneumonitis than in those without HCMV pneumonitis. Although ganciclovir treatment was very effective in treating HCMV pneumonitis and suppressing HCMV DNA levels, thrice weekly ganciclovir prophylaxis only partially controlled HCMV DNA levels and did not eliminate HCMV pneumonitis risk as three patients developed HCMV pneumonitis while on this regimen. CONCLUSIONS: HCMV DNA detection, absolute levels, and relative change from baseline in the PBL of LTR correlate with HCMV pneumonitis episodes and may be a useful intermediate outcome measure of the efficacy of ganciclovir prophylaxis and treatment strategies.
Assuntos
Infecções por Citomegalovirus , Citomegalovirus/genética , DNA Viral/análise , Leucócitos/virologia , Transplante de Pulmão , Pneumonia/virologia , Adulto , Antivirais/uso terapêutico , Sangue/virologia , Estudos de Coortes , Citomegalovirus/efeitos dos fármacos , Citomegalovirus/isolamento & purificação , Infecções por Citomegalovirus/sangue , Infecções por Citomegalovirus/genética , Infecções por Citomegalovirus/prevenção & controle , Infecções por Citomegalovirus/virologia , Feminino , Ganciclovir/uso terapêutico , Humanos , Masculino , Pessoa de Meia-Idade , Pneumonia/genética , Pneumonia/prevenção & controle , Período Pós-Operatório , Carga ViralRESUMO
Cytomegalovirus viral load measurement is a powerful new tool for monitoring of CMV disease; however, the optimal strategy for use is unknown. Weekly plasma CMV viral loads and CMV-related outcomes were monitored in 46 consecutive allogeneic bone marrow transplantation (BMT) recipients receiving standardised antiviral prophylaxis. A total of 412 CMV viral loads were quantitated in the first 100 days post transplantation with 77 positive samples (19%) in 20 patients (43%). No patient with all negative CMV viral load results developed CMV disease. Two of three patients with highly positive CMV viral loads (first positive < or =30 days post transplant, maximum viral load > or =5000 copies/ml, and > or =50% of samples positive) developed CMV disease. A total of 17 patients with positive CMV viral loads, who did not meet the criteria for highly positive, did not develop CMV disease. CMV viral load detection was higher in recipients who were CMV sero-positive. In conclusion, CMV disease did not occur in the setting of a persistently negative CMV viral load. A positive CMV viral load result occurred commonly after allogeneic BMT, even in patients receiving antiviral prophylaxis.
Assuntos
Antivirais/administração & dosagem , Transplante de Medula Óssea/efeitos adversos , Infecções por Citomegalovirus/diagnóstico , Infecções por Citomegalovirus/prevenção & controle , Ganciclovir/administração & dosagem , Carga Viral , Doença Aguda , Adolescente , Adulto , Doença Crônica , Infecções por Citomegalovirus/tratamento farmacológico , Feminino , Seguimentos , Doença Enxerto-Hospedeiro/diagnóstico , Doença Enxerto-Hospedeiro/mortalidade , Humanos , Masculino , Pessoa de Meia-Idade , Estudos ProspectivosRESUMO
Although widely used outside the United States, bacillus of Calmette and Guérin (BCG) immunization generally is given scant consideration in the US literature. We believe that the recent resurgence of tuberculosis, including multidrug-resistant tuberculosis, is a compelling argument for the use of BCG in healthcare workers and that BCG given to those at risk of exposure could be more effective than routine tuberculin skin testing and isoniazid prophylaxis
Assuntos
Antibioticoprofilaxia , Antituberculosos/uso terapêutico , Vacina BCG , Pessoal de Saúde , Isoniazida/uso terapêutico , Tuberculose Resistente a Múltiplos Medicamentos/prevenção & controle , Austrália , Humanos , Teste TuberculínicoRESUMO
An outbreak of gastroenteritis caused by Norwalk-like virus occurred in two areas of the hospital: area 1, consisting of three adjacent and interconnected wards, with mostly elderly patients; and area 22, an acute ward in a separate building with elderly patients. In area 1, 40 patients and 20 staff were affected; in area 2, 18 patients and 14 staff were affected. Infection control measures were instituted in consultation with the government health authority. These measures did not appear to affect the course of the outbreak, but may have prevented spreads to the other wards.
Assuntos
Infecções por Caliciviridae/epidemiologia , Infecção Hospitalar/epidemiologia , Surtos de Doenças , Gastroenterite/epidemiologia , Vírus Norwalk , Idoso , Idoso de 80 Anos ou mais , Austrália/epidemiologia , Infecções por Caliciviridae/prevenção & controle , Infecções por Caliciviridae/transmissão , Infecção Hospitalar/virologia , Gastroenterite/prevenção & controle , Gastroenterite/virologia , Hospitais , Humanos , Casas de SaúdeRESUMO
BACKGROUND: Needleless intravenous devices have now been implemented by many institutions worldwide. A rationale for their use has been a reduction in the number of needlestick injuries. OBJECTIVE: The aim of this review is to outline the possible benefits and dangers of needleless intravenous systems. REVIEW: Many early reports demonstrate a reduction in needlestick injuries after the implementation of a needleless intravenous device; however, not all such reductions are directly attributable to the device itself. Furthermore, good evidence suggests that needlestick accidents prevented by needleless intravenous devices pose little threat to health care workers. Finally, increasing reports associate bacteremias with the use of needleless intravenous devices. Early reports described devices used in the home care setting; however, recent reports are from acute health care settings, including intensive care units. CONCLUSION: Ongoing critical review of the benefits, risks, and costs of needleless intravenous devices is required.